타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv) AbbVie·c-Met 12 trials·t½ ADC in the range of days; free MMAE shorter | |
|---|---|---|
Overview Program | Emrelis (telisotuzumab vedotin) | Telisotuzumab Adizutecan |
Overview Company | AbbVie | AbbVie |
Overview Modality | ADC | ADC |
Overview Target | c-Met | Non Small Cell Lung Carcinoma |
Overview Indication | Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression | Metastatic Colorectal Cancer |
Overview Phase | APPROVED | PHASE_2 |
Overview Status | APPROVED | RECRUITING |
Overview Content status | Curated Core | Standard Database |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · structured catalog |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | Selects high c-Met protein overexpression by IHC, not MET gene mutation. That split is the first row versus MET TKIs. | — |
Positioning Known limitation | c-Met down-regulation, MMAE efflux, and histologic transformation. | — |
Positioning Development positioning | 2L+ | — |
Technology Payload | MMAE (microtubule inhibitor) | — |
Technology Linker | Cleavable vc linker, vedotin chemistry | — |
MoA Mechanism | Anti-c-Met antibody binds and internalizes; the protease-cleavable linker releases MMAE, which disrupts microtubules and kills the cell plus neighbors via bystander diffusion. | — |
MoA Biomarker | VENTANA MET (SP44) companion diagnostic. High overexpression is ≥50% of cells with 3+ staining, not MET exon 14 skipping. | biomarker analyses showed ORR enrichment in patients with higher c-Met protein expression and MET focal ampli |
PK/PD Half-life | ADC in the range of days; free MMAE shorter | — |
PK/PD Animal (cat.) | Human | — |
Toxicology Major finding | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. | — |
Toxicology CRS | N/A | — |
Clinical Safety signal | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. | — |
Clinical Program phase | APPROVED | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv) AbbVie·c-Met 12 trials·t½ ADC in the range of days; free MMAE shorter | |
|---|---|---|
Overview Program | Emrelis (telisotuzumab vedotin) | Telisotuzumab Adizutecan |
Overview Company | AbbVie | AbbVie |
Overview Modality | ADC | ADC |
Overview Target | c-Met | Non Small Cell Lung Carcinoma |
Overview Indication | Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression | Metastatic Colorectal Cancer |
Overview Phase | APPROVED | PHASE_2 |
Overview Status | APPROVED | RECRUITING |
Overview Content status | Curated Core | Standard Database |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · structured catalog |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | Selects high c-Met protein overexpression by IHC, not MET gene mutation. That split is the first row versus MET TKIs. | — |
Positioning Known limitation | c-Met down-regulation, MMAE efflux, and histologic transformation. | — |
Positioning Development positioning | 2L+ | — |
Technology Payload | MMAE (microtubule inhibitor) | — |
Technology Linker | Cleavable vc linker, vedotin chemistry | — |
MoA Mechanism | Anti-c-Met antibody binds and internalizes; the protease-cleavable linker releases MMAE, which disrupts microtubules and kills the cell plus neighbors via bystander diffusion. | — |
MoA Biomarker | VENTANA MET (SP44) companion diagnostic. High overexpression is ≥50% of cells with 3+ staining, not MET exon 14 skipping. | biomarker analyses showed ORR enrichment in patients with higher c-Met protein expression and MET focal ampli |
PK/PD Half-life | ADC in the range of days; free MMAE shorter | — |
PK/PD Animal (cat.) | Human | — |
Toxicology Major finding | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. | — |
Toxicology CRS | N/A | — |
Clinical Safety signal | Peripheral neuropathy, fatigue, decreased appetite, and peripheral edema are common. Grade 3–4 lab signals include lymphopenia and transaminase rises. | — |
Clinical Program phase | APPROVED | PHASE_2 |
추천 비교
추천 비교